Acne is one of the most common diseases worldwide and affects approximately 50 million individuals in the United States. Oral antibiotics are the most common systemic agent prescribed for the treatment of acne. However, their use may be associated with a variety of adverse outcomes including bacterial resistance and disruption of the microbiome. As a result, multiple treatment guidelines call for limiting the use of oral antibiotics in the treatment of acne, although actual prescribing often does not follow these guidelines. In this review, the rationale for concerns regarding the use of oral antibiotics for the management of acne is reviewed. In addition, we will discuss our approach to complying with the intent of the guidelines, with a focus on novel topical agents, dietary modification, laser and light-based modalities, and systemic medications such as spironolactone, combined oral contraceptives, and oral isotretinoin. Antibiotic resistance is a growing problem across medicine and rates of antibiotic resistance among isolates of Cutibacterium (formerly Propionibacterium) acnes have been rising, including to tetracycline-class antibiotics. 1-4 In addition to resistance among C. acnes, the use of oral antibiotics is associated with disruption of the normal flora, bacterial resistance among other organisms, and increased rates of upper respiratory infection and pharyngitis. 5-8 Antibiotic use may also be associated with inflammatory bowel disease and collagen vascular disease. 7-16 Finally, there may be an association between the use of oral tetracycline-class antibiotics and risk of breast and colon cancer. 17,18 As a result, there have